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Abstract Interrupting myocardial reperfusion with
intermittent episodes of ischemia (i.e., postconditioning)
during primary percutaneous coronary intervention (PPCI)
has been suggested to protect myocardium in ST-segment
elevation myocardial infarction (STEMI). Nevertheless,
trials provide inconsistent results and any advantage in
long-term outcomes remains elusive. Using a retrospective
study design, we evaluated the impact of balloon inflations
during PPCI on enzymatic infarct size (IS) and long-term
outcomes. We included 634 first-time STEMI patients
undergoing PPCI with an occluded infarct-related artery
and adequate reperfusion thereafter and divided these into:
patients receiving 1–3 inflations in the infarct-related artery
[considered minimum for patency/stent placement (con-
trols); n = 398] versus C4 [average cycles in clinical
protocols (postconditioning analogue); n = 236]. IS,
assessed by peak creatine kinase, was lower in the post-
conditioning analogue group compared with controls
[median (interquartile range) 1,287 (770–2,498) vs. 1,626
(811–3,057) UI/L; p = 0.02], corresponding to a 21 % IS
reduction. This effect may be more pronounced in women,
patients without diabetes/hypercholesterolemia, patients
presenting within 3–6 h or with first balloon re-occlusion
B1 min. No differences were observed in 4-year mortality
or MACCE between groups. Four or more inflations during
PPCI reduced enzymatic IS in STEMI patients under well-
defined conditions, but did not translate into improved
long-term outcomes in the present study. Large-scale ran-
domized trials following strict postconditioning protocols
are needed to clarify this effect.
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Introduction
In patients presenting with ST-segment elevation myocar-
dial infarction (STEMI), infarct size (IS) can be limited by
early myocardial reperfusion via primary percutaneous
coronary intervention (PPCI), thereby preserving left
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ventricular systolic function and improving clinical out-
come. However, the full benefits of myocardial reperfusion
are not realized, given that the process of restoring blood
flow to the ischemic myocardium can independently induce
cell death (i.e., lethal reperfusion injury) [13]. Hence,
cardioprotective strategies that potentially modify the
conditions of reperfusion and limit reperfusion injury are of
major clinical interest.
Ischemic postconditioning (IPOC) is an interventional
strategy in which controlled, brief, intermittent episodes of
re-occlusions in the first few minutes of reperfusion can
protect myocardium from lethal reperfusion injury [28]. The
concept of interrupting the myocardial reperfusion process
with the angioplasty balloon to reduce myocardial IS (as
assessed by different modalities, including cardiac biomark-
ers) has been demonstrated to be efficacious in several small-
size studies evaluating STEMI patients undergoing PPCI [10,
19, 21, 26]. However, recent trials provide inconsistent
results [4–6, 18, 20]. The efficacy of IPOC appears to be
hampered by various confounders and additionally, uncer-
tainties remain about the optimal protective IPOC protocol
[12]. More importantly, the effect of IPOC on long-term
clinical endpoints such as mortality or major adverse cardiac
and cerebrovascular events (MACCE) remains unknown.
In the absence of adequately powered clinical trials, we
aimed to investigate the impact of multiple balloon infla-
tions during PPCI on enzymatic IS in patients with STEMI.
Accordingly, we aimed to determine whether this may have
served as a real-world analogue for IPOC. Secondly, to
assess potential confounders, we evaluated whether these
effects differed in prespecified subgroups. Finally, we
examined the impact of balloon inflations during PPCI on
long-term clinical outcome.
Methods
Study design and population
As the principal regional cardiac referral center, an ongo-
ing registry of catheter-based coronary procedures is
maintained in an electronic database at our institution. We
conducted a retrospective chart review, together with the
electronic medical records, of all patients who presented to
our institution between June 2006 and June 2010 with
STEMI undergoing PPCI. We included patients if they:
were C18 years of age; had symptoms suggesting acute
myocardial ischemia lasting [30 min and ST-segment
elevation [0.1 mV in C2 contiguous leads; had an occlu-
ded infarct-related artery (IRA) with TIMI-0/1 flow on
initial angiogram; had adequate reperfusion after PCI
(TIMI-3). We excluded patients with previous myocardial
infarction or CABG, cardiogenic shock, cardiac arrest or
thrombectomy. The current retrospective study design was
modeled after the study by Darling and colleagues [3].
Ethics
Patients were not subject to acts for the purpose of this
retrospective study. Neither was any mode of behavior
imposed, otherwise than their regular treatment. Therefore,
according to Dutch law, written informed consent for a
patient to be enrolled in this study was not required. This
study was conducted according to the Erasmus MC Privacy
Policy and regulations for the appropriate use of data in
patient oriented research and was approved by the institu-
tional ethics committee.
Procedures and medications
All procedures were performed following standard proce-
dural guidelines at the time. Intraprocedural anticoagulation
was ensured using unfractionated heparin (to achieve an
activated clotting time [250 s in all patients). All patients
received an aspirin loading dose of 300 mg and were
encouraged to continue this regimen indefinitely. After a
600 mg clopidogrel loading dose, additional antiplatelet
therapy with a 75 mg clopidogrel maintenance dose was
instituted in all patients, who were then advised to continue
this regimen for 12 months. In all cases, the interventional
strategy, including pre-dilatation, post-dilatation, glyco-
protein IIb/IIIa inhibitors (to prevent or to treat distal mi-
croembolization) and other medications such as adenosine,
was at the discretion of the interventional cardiologist.
Balloon inflations
In the currently available clinical trials, the IPOC protocols
consisted of 2–4 cycles of ischemia and reperfusion (pro-
duced by inflations/deflations of angioplasty balloon) after
direct stenting [27]. Taking into account an average of
three cycles utilized in the clinical protocols plus one
balloon inflation for direct stenting, we reasoned that C4
inflations would mimic an IPOC stimulus in a real-world
setting. Thus, the study population was divided into
patients receiving 1–3 balloon inflations during PPCI in the
IRA (considered minimum range for achieving patency/
stent placement [controls]) and patients receiving C4
(analogue for IPOC). The definition of study population by
Darling et al. [3] served as a model for the current
description. The number of balloon inflations, the average
duration of inflations and the delay between first and sec-
ond inflation during PPCI were obtained from our cathe-
terization laboratory’s procedure database. In this
electronic database, each balloon inflation and its location
and duration in the coronary artery tree during the
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procedure is immediately registered, by a cathlab techni-
cian using an angioplasty timer, upon indication by the
interventional cardiologist. The delay of first re-occlusion
after reflow was defined as the time period between first
and second balloon inflation. Clinical indications for mul-
tiple balloon inflations in the IRA were: long or multiple
lesions requiring [1 pre-dilatation, the placement of C2
stents or the need for [1 post-dilatation.
Study endpoints and follow-up
The primary study endpoint was enzymatic IS assessed by
peak CK release and was defined as the highest serum
concentration in the 72-h time period after the intervention.
The upper limit of normal was 180 U/L. The secondary
clinical endpoints included all-cause mortality and MAC-
CE during 4-year follow-up. MACCE was defined as a
composite of all-cause mortality, non-fatal myocardial
infarction, PCI, CABG or stroke. Survival data for all
patients were obtained from municipal civil registries. A
questionnaire was subsequently sent to all living patients
with specific questions on rehospitalization for MACCE.
For patients who suffered an adverse event at another
centre, medical records or discharge letters from the other
institutions were systematically reviewed.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD) or median with interquartile range (IQR),
depending on normal distribution and were compared using
the Student t test or Mann–Whitney U test as appropriate.
Categorical variables are presented as percentages and
were compared using the Chi-square test. Univariable and
multivariable linear regression analyses were performed to
evaluate the relationship between number of balloon
inflations with peak CK after logarithmic transformation.
In multivariable analyses the variables age, gender, dia-
betes, number of diseased vessels, symptom-to-balloon
time, Rentrop collateral grade, proximal occlusion of either
left anterior descending (LAD) or right coronary artery
(RCA) and number of balloon inflations were entered into
the model. The differences of median peak CK with 95 %
confidence intervals (CI) in subgroups were estimated
using the Hodges–Lehmann method for the location shift
according to the following prespecified variables: gender,
age, diabetes, hypercholesterolemia, hypertension, collat-
erals, vessel disease, culprit artery, delay first re-occlusion,
and symptom-to-balloon time. Patients lost to follow-up
were considered at risk until the date of last contact, at
which time-point they were censored. Clinical outcomes
are presented as Kaplan–Meier survival estimates and were
compared using the log-rank test. Multivariable Cox
proportional hazard regression analyses were performed to
evaluate the relationship between number of balloon
inflations and all-cause mortality and MACCE, and are
presented as unadjusted and adjusted hazard ratios (HR)
with associated 95 % CIs.
The Hodges–Lehmann analysis was performed using
SAS version 9.2 (SAS Institute, Cary, NC, USA). All other
statistical analyses were performed using SPSS version 20
(SPSS, Inc., Chicago, Illinois, USA). All statistical tests




Between June 2006 and June 2010 a total of 2,520 STEMI
patients presented to our institution for PPCI, of which
1,086 met the eligibility criteria. Of these, patients without
available cardiac enzymes (n = 306) and patients without
available balloon inflation data (n = 146) were excluded.
Thus, the current analysis included 634 patients (n = 398
in the control group and n = 236 in the IPOC analogue
group) (Fig. 1). Baseline, angiographic, and procedural
characteristics are listed in Table 1. Patients in the IPOC
Fig. 1 Study flow diagram. CK creatine kinase, IPOC ischemic
postconditioning, IRA infarct-related artery, MACCE major adverse
cardiac and cerebrovascular events, PPCI primary percutaneous
coronary intervention, STEMI ST-segment elevation myocardial
infarction





Data are presented as %, mean
(SD) or median (IQR)
MACCE major adverse cardiac
events, ACE-i/ARB angiotensin-
converting enzyme inhibitor or
angiotensin II receptor blocker,
LAD left anterior descending
coronary artery, LCx left






a Patients receiving 1–3 balloon
inflations
b Patients receiving C4 balloon
inflations
c Left main only or in
combination with 1-, 2- or
3-vessel disease




e For patients with ischemic
times [12 h, median symptom
onset-to-balloon time (with
interquartile range) was 16.1 h
(13.1–21.5) in the control group
(n = 17) and 16.5 h (14.1–21.6)







Clinical characteristics and risk factors
Age (years) 59.9 ± 13.0 62.8 ± 12.6 0.006
Male 75.1 71.6 0.33
Hypertension 38.4 41.0 0.51
Diabetes 10.3 9.7 0.82
Hypercholesterolemia 34.4 36.1 0.67
Current smoker 49.0 39.8 0.03
Family history 35.6 36.3 0.86
Angiographic and procedural characteristics
Infarct-related artery
LAD 40.7 36.9 0.34
LCx 17.8 16.1 0.58
RCA 41.5 47.0 0.17
No. of diseased vessels
1 64.1 44.5 \0.001
2 19.6 30.5 0.002
3 14.6 19.1 0.14
Left main, anyc 1.8 5.9 0.005
Collaterals
Rentrop flow grade 0 81.4 77.7 0.27
Rentrop flow grade 1 11.7 10.0 0.52
Rentrop flow grade 2 5.4 8.3 0.15
Rentrop flow grade 3 1.5 3.9 0.06
TIMI flow in culprit artery before PCI
TIMI 0 88.9 89.4 0.86
TIMI 1 11.1 10.6 0.86
Symptom onset-to-balloon time
B3 h 41.3 35.7 0.19
3–6 h 39.7 39.5 0.97
6–12 h 14.4 17.1 0.38
[12 he 4.6 7.6 0.14
Symptom onset-to-balloon time (h) 3.3 (2.4–5.1) 3.8 (2.4–5.9) 0.19
Glycoprotein IIb/IIIa inhibitor use 30.2 36.0 0.13
Adenosine use 0.5 0.8 0.60
Balloon inflation data
Average balloon inflation time (s) 11.7 (9.5–15.0) 11.6 (9.7–15.7) 0.49
Average balloon inflation pressure (atm) 16.0 (14.0–19.3) 15.0 (12.8–17.0) \0.001
Delay 1st re-occlusion after reflow (min) 4.0 (2.0–7.0) 3.0 (1.0–6.0) 0.03
Medication during hospitalization in interventional centred
Aspirin 99.7 100 0.44
Thienopyridine 100 100 –
ACE-i/ARB 3.8 5.0 0.48
b-blocker 50.9 48.6 0.59
Statin 85.1 86.3 0.69
Calcium channel blocker 5.7 7.3 0.44
Diuretic 1.1 1.4 0.76
Nitrate 24.4 25.0 0.87
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analogue group were older, were less frequently smokers,
had less single-vessel and more multivessel disease, and
had a tendency of having more Rentrop grade 3 collaterals
compared to controls.
Balloon inflation data
The patients in the IPOC analogue group received a median
of 5 balloon inflations during PPCI, compared with 2
inflations in controls (p \ 0.0001) (Fig. 2a). The balloon
inflation time and pressure in the IPOC analogue group
were 11.6 s (9.7–15.7) and 15.0 atm (12.8–17.0), com-
pared to 11.7 s (9.5–15.0) (p = 0.49) and 16.0 atm
(14.0–19.3) (p \ 0.001) in the control group, respectively.
The delay of first re-occlusion was 3.0 min (1.0–6.0) in the
IPOC analogue group, compared to 4.0 min (2.0–7.0) in
controls (p = 0.03) (Table 1).
Infarct size
Peak CK release was significantly lower in the IPOC
analogue group compared with controls [1,287 (770–2,498)
vs. 1,626 (811–3,057) UI/L; p = 0.02] (Fig. 2b). The
lower peak CK values in the IPOC analogue group
appeared to be more pronounced in: women, patients
without diabetes or hypercholesterolemia, patients pre-
senting within 3–6 h of symptom onset, and patients with
delay of first re-occlusion B1 min (Fig. 2c).
Fig. 2 Balloon inflations and
enzymatic infarct size. Number
of inflations (a), peak creatine
kinase release in the
postconditioning analogue
group versus controls in the
overall study group (b) and
differences of median peak
enzyme release with 95 %
confidence intervals between
study groups according to
relevant patient subgroups (c).
The reference for the difference
is 1–3 inflations, thus, a
negative difference indicates a
lower peak creatine kinase in
those with C4 inflations (c). CI




multivessel disease, SVD single-
vessel disease
Basic Res Cardiol (2014) 109:403 Page 5 of 10
123
Long-term outcomes
Clinical follow-up for mortality was available for 614
patients (97 %). There were 51 deaths during the follow-
up: 21 deaths occurred in the IPOC analogue group and 30
deaths occurred in the control group (Kaplan–Meier esti-
mates of 4-year mortality of 10.0 and 9.0 %, respectively;
adjusted HR 0.86, 95 % CI 0.44–1.67; p = 0.65). Clinical
follow-up for MACCE was available for 583 patients
(92 %). There were 108 MACCEs during the follow-up: 44
events occurred in the IPOC analogue group and 64 events
occurred in the control group (Kaplan–Meier estimates of
4-year MACCE of 24.8 and 26.8 %, respectively; adjusted
HR 0.87, 95 % CI 0.57–1.33; p = 0.52) (Table 2; Fig. 3).
Discussion
The present analysis showed that STEMI patients receiving
C4 balloon inflations during PPCI displayed lower peak
CK values compared with patients receiving 1–3 inflations,
corresponding to an enzymatic IS reduction of 21 %. This
finding adds further credence to the concept that inter-
rupting the reperfusion procedure with several intermittent
episodes of re-occlusions (produced by inflations of the
angioplasty balloon) may have acted as a real-world ana-
logue for IPOC and thereby attenuated reperfusion injury.
Although the overall beneficial effect remained similar, the
lower peak CK values in the IPOC analogue group may be
more pronounced in women, patients without diabetes or
hypercholesterolemia, patients presenting within 3–6 h of
symptom onset and patients with a delay of first re-occlu-
sion B1 min. There were no differences in the rates of
mortality or MACCE during 4-year follow-up between the
IPOC analogue group and the control group in the current
study.
Previous studies
Although it has been demonstrated that IPOC reduced IS
with [19, 21, 26] or without [9] an improvement in left
ventricular function in the clinical setting, not all studies
have been positive [4, 5, 18, 20]. Recently, it was reported
that IPOC was not able to reduce IS or improve left ven-
tricular function (assessed by cardiac magnetic resonance
imaging) in 79 first-time STEMI patients presenting for
PPCI within 12 h of symptom onset [5]. Likewise, Tar-
antini et al. [20] failed to demonstrate any advantage of
IPOC in terms of IS reduction assessed by cardiac mag-
netic resonance or myocardial reperfusion markers. How-
ever, in this trial, the proportion of diabetics was not
balanced between study groups (18 % in IPOC group vs.
3 % in controls; p = 0.056), which may have blunted the
effects of IPOC. Also, it may well be that in patients with
symptom-to-balloon times\12 h, a specific IPOC protocol
may be ineffective. Importantly, the eligibility criteria
differed substantially in the currently available clinical
IPOC trials, along with the defined study endpoints [27]. Of
these, serum CK release is the most widely used study




95 % CI p Hazard
ratioa
95 % CI p
Mortality 1.21 0.69, 2.11 0.50 0.86 0.44, 1.67 0.65
MACCE 1.22 0.83, 1.79 0.31 0.87 0.57, 1.33 0.52
CI confidence interval, MACCE major adverse cardiac and cerebro-
vascular events
a The multivariable Cox-regression model included age, gender,
diabetes, number of diseased vessels, symptom-to-balloon time,
Rentrop collateral grade, proximal occlusion of either left anterior
descending (LAD) or right coronary artery (RCA) and number of
balloon inflations
Fig. 3 Kaplan–Meier curves of 4-year mortality and major adverse cardiac and cerebrovascular events
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endpoint [8] and peak CK values strongly correlate with IS
and predict cardiac outcomes in STEMI patients treated
with PPCI [2, 7]. Currently, no biomarker exists that con-
firms whether a specific IPOC protocol induced a ‘‘post-
conditioned’’ state [24]. Nevertheless, assessment of
myocardial damage after STEMI is crucial in evaluating
the efficacy of reperfusion therapy and predicting progno-
sis. For instance, most recently Hahn et al. [6] failed to
demonstrate any advantage of IPOC in terms of reperfusion
markers as assessed by complete ST-segment resolution
([70 %) 30 min post-PCI and postprocedural TIMI flow or
myocardial blush grade in a large randomized trial
involving 700 STEMI patients. The current results are in
line with previous randomized studies, in which IPOC
resulted in IS reduction ranging from 27 to 40 % as mea-
sured by CK release [19, 21, 23, 26]. The current results are
also in agreement with two retrospective studies involving
115 and 85 STEMI patients in which C4 [3] or C3 [25]
balloon inflations during PPCI were associated with lower
peak CK values compared with 1–3 or 1–2 inflations. The
present study extends these observations by assessing
potential confounders and evaluating the association
between balloon inflations and long-term clinical outcomes
after PPCI in a large cohort of 634 patients. Still, important
differences remain with the aforementioned (positive and
negative) randomized trials when considering the major
determinants of IS. The current study included a proportion
of patients with collateral circulation, patients with a wide
range of ischemic times, and patients with both LAD and
non-LAD infarctions (the latter representing usually
smaller areas at risk). In this regard it is noteworthy that the
exclusion of patients with Rentrop 2/3 collateral grades
(n = 55) from the study cohort did not change the bene-
ficial effect of C4 balloon inflations during PPCI on
enzymatic IS in the IPOC analogue group compared with
controls (p = 0.04). In addition, we adjusted for these
determinants in the regression analysis, including the
influence of collateral score.
Long-term clinical outcomes
The beneficial effect of C4 balloon inflations during PPCI
on peak CK release in the current study did not translate
into improved 4-year clinical outcomes. The reasons for
these observations could be related to a number of factors.
First, multivessel disease was more often encountered
among patients in the IPOC analogue group compared with
controls. Consequently, these patients were more likely to
receive staged procedures for repeat revascularizations.
Second, reperfusion therapy (PCI and thrombolysis) has
already reduced mortality after acute myocardial infarction
to low levels (4–6 %) [1], making further significant
reductions by adjunctive therapies difficult to achieve. In
fact, IS may not impact outcomes such as mortality until a
threshold IS is achieved. In the current study, IS (peak CK
values of 1,287 vs. 1,626 UI/L in study groups) was
smaller compared to earlier retrospective studies (1,655 vs.
2,272 UI/L [3]; 2,056 vs. 2,603 UI/L [25]). With the rel-
atively small overall IS and current mortality rates, the
present study was likely to be underpowered to discern
differences in all-cause mortality. Therefore, no definite
conclusions can be drawn regarding the impact of IPOC on
long-term outcomes. This is especially true, when consid-
ering that most recently both remote ischemic pre- [22] and
perconditioning [17] have been found to improve long-
term outcomes in prospective randomized trials, including
all-cause mortality, in the setting of CABG and STEMI,
respectively. Nevertheless, it is reassuring to observe no
excess clinical events in the IPOC analogue group in the
present study.
IPOC mechanisms and potential confounders
The current mechanistic paradigm for IPOC invokes the
activation of signal transduction pathways by autacoid
triggers, which accumulate extracellularly in response to
the IPOC stimulus and act on their cell surface receptors or
other molecular targets. Ultimately, signaling pathways
activated by IPOC probably converge on mitochondria to
inhibit the opening of the mitochondrial permeability
transition pore, thereby preventing myocardial cell death
[12]. Many of these cellular signaling elements might be
affected by confounders, co-morbidities or co-medication,
as these conditions are associated with fundamental
molecular alterations potentially affecting responses to
IPOC [12]. Currently, there is insufficient information to
judge how and to what extent several confounding factors,
including cardiovascular risk factors, gender, and age
influence IPOC efficacy in the clinical setting. In this light,
we investigated the effect of C4 balloon inflations (as a
real-world analogue for IPOC) compared with controls in
various predefined subgroups. Patients in the IPOC ana-
logue group displayed lower peak CK values compared
with controls in nearly all subgroups with a possibly more
pronounced effect in women and patients without diabetes
or hypercholesterolemia, among others (Fig. 2c). At pres-
ent, there is no strong evidence whether IPOC-induced
protection is gender-dependent [12]. Nevertheless, the
current observation is not consistent with a recent meta-
analysis in which a pronounced cardioprotective effect of
IPOC in male patients was reported [29]. Conversely,
although statistically not significant (p = 0.16), patients
with diabetes displayed higher peak CK concentrations in
the IPOC analogue group. This finding is compatible with
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observations from the pre-clinical setting, in which IPOC-
induced cardioprotection was shown to be impaired in
diabetes: the IS-limiting effect was lost or required extra
cycles of ischemia/reperfusion in various animal models of
diabetes [11].
IPOC protocol and protection
There is consensus that the delay in applying the first re-
occlusion after reflow must be relatively short (\1 min)
for exerting the beneficial effects of IPOC [24]. In the
present study, there was a significant beneficial effect in
the IPOC analogue group when this delay was indeed
within 1 min, whereas delaying the first re-occlusion
above 1 min lowered the efficiency (Fig. 2c). In this
regard, one practical issue potentially interfering with
IPOC is the use of manual aspiration thrombectomy. This
technique usually re-establishes a significant blood flow in
the IRA and the delay between applying the procedure
and initiating the IPOC protocol might exceed the very
short time frame in which IPOC has been shown to be
efficient. For this reason, we excluded patients receiving
thrombectomy from the present analysis. In the current
study, median delay of first re-occlusion after reflow was
3.0 min in the IPOC analogue group. In contrast, in the
excluded thrombectomy patients (n = 130), median delay
was 6.7 min. Indeed, when performing a sensitivity ana-
lysis by including the thrombectomy cohort into the
current study, median delay of first re-occlusion became
4.0 min in the IPOC analogue group (and even 8.0 min in
patients receiving thrombectomy in the IPOC analogue
group). Additionally, the beneficial effect of C4 balloon
inflations during PPCI on enzymatic IS in the IPOC
analogue group (n = 484) compared to controls
(n = 280) lost its statistical significance [median peak CK
(interquartile range) 1,429 (790–2,761) vs. 1,637
(802–3,114) UI/L; p = 0.09] when including the throm-
bectomy cohort. Future studies need to explore this issue
in a randomized setting. On the other hand, despite a
median first re-occlusion delay of 3 min (1.0–6.0) in the
IPOC analogue group, the use of C4 inflations was still
associated with lower peak CK values. This observation is
in agreement with recent findings in which delaying the
IPOC stimulus [1 min after reperfusion onset did not
abrogate cardioprotection in the in vivo mouse heart [15]
and may suggest that IPOC [1 min may still confer
cardioprotection in a clinical setting. Nevertheless, the
optimal time window for application of IPOC remains to
be determined.
At present, uncertainties remain about the most effective
IPOC algorithm in the clinical setting, including number
and duration of re-occlusions [24]. In an attempt to define
the optimal algorithm in the current cohort, we compared
patients receiving a single balloon inflation with the mul-
tiple inflation groups. We were not able to ascertain that
one particular inflation group was significantly associated
with reduced peak CK values (data not shown).
A similar predicament also exists regarding the total
duration of the index ischemia. A certain IPOC algorithm
applied after an index ischemia of 30 or 45 min signifi-
cantly reduced IS, but not after an index ischemia of
60 min or longer in a pre-clinical model [16]. Also, with
too brief index ischemia, IPOC failed to reduce IS [14].
Hence, there is a need to define the optimal protective
protocol for a given duration of the index ischemia. In the
current analysis, patients presenting within 3–6 h may have
accrued the greatest benefit in the IPOC analogue group.
Surprisingly, patients with short ischemic times (\3 h) and
those presenting more than 12 h following symptom
onset also favored C4 balloon inflations. This observation
might be especially important as the relationship between
extent of myocardial reperfusion injury and very short or
very long ischemic times have not been fully elucidated.
Limitations
The current study suffers from inherent limitations of a
non-randomized trial and thus should be considered as a
hypothesis-generating post hoc analysis. There were sig-
nificant differences between study groups in terms of
baseline characteristics. To compensate for these differ-
ences, we have performed adjustments employing regres-
sion and multivariate analyses. PPCI procedures in routine
practice were unable to mimic a strict IPOC protocol uti-
lized in randomized trials. Hence, we do not consider C4
balloon inflations during PPCI as a surrogate for IPOC.
Nonetheless, we limited our analysis to those patients
exhibiting a fully occluded IRA and a postprocedural
TIMI-3 flow, both representing essential conditions for
therapeutic application of IPOC, and were able to dem-
onstrate a beneficial effect on enzymatic IS. Accordingly,
our data underscore the need for further prospective stud-
ies. We were unable to directly quantify the area at risk in
the study population due to the retrospective study design.
In an attempt to adjust for (relatively) large volumes at risk,
we corrected for proximal LAD or RCA infarctions. The
possibility remains that true peak enzyme values were
missed. Nevertheless, blood sampling as performed in this
study reflects routine clinical practice. Although we did not
collect the exact time points of the measurements, we used
the highest biomarker concentration in the 72-h time period
post-intervention. We were unable to report on co-medi-
cation of patients with pre-existing risk factors at the time
of presentation, as certain pharmacological agents (e.g.,
angiotensin-converting enzyme inhibitors) have been
shown to impact on IS reduction by IPOC in animal models
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[12]. However, we reported the prescription rates of
pharmacological therapies during hospitalization which
was not different between groups, possibly reflecting their
chronic use. Moreover, by performing subgroup analyses,
we provided insight into the efficacy of multiple balloon
inflations in the absence or presence of cardiovascular risk
factors. Despite the large number of patients in the current
study (n = 634) and 97 % available 4-year follow-up, only
51 deaths occurred. This low mortality rate likely reflects
the relatively small infarct sizes in our study population.
The latter may, in turn be a consequence of not limiting the
analysis to patients with proximal lesions (associated with
larger volumes at risk). We were unable to report on car-
diac death, and the potential misclassification by the use of
all-cause mortality in the composite MACCE may have
resulted in an underestimation of the relationship between
C4 balloon inflations during PPCI and outcome. More
importantly, an a priori power analysis was not conducted
due to the retrospective nature of the study, and with the
generally small infarcts and low mortality rates, the present
study likely lacks the statistical power to discern differ-
ences in all-cause mortality.
Conclusion
The present study suggests that the use of C4 balloon
inflations during PPCI reduces enzymatic IS in patients
with STEMI under well-defined conditions. This effect
may be more pronounced in women, patients without
diabetes or hypercholesterolemia, those presenting within
3–6 h, and those with first re-occlusion delay B1 min. This
hypothesis-generating study suggests that C4 inflations
during PPCI may have served as a real-world IPOC stim-
ulus and possibly may reflect the phenomenon’s potential
in routine clinical practice. Although we present unique
data concerning long-term clinical outcomes, adequately
powered randomized trials are necessary with strict
adherence to IPOC protocol to determine whether a
reduction in IS by IPOC translates into improved clinical
outcomes.
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